bluuebunny/crossref_metadata_2025_split huggingface dataset:
First-line anti-TNF agents, ustekinumab and vedolizumab perform similarly in Crohn’ disease, but not in ulcerative colitis
Authors: Supovec Eva , Hanžel Jurij , Novak Gregor , Manevski Damjan , Štabuc Borut , Drobne David 
Published: February 2025

Background
Real-word comparisons between first-line biologicals in inflammatory bowel disease (IBD) are scarce.

Aims
The aim of this study is to compare drug persistence and patient reported outcome-2 (PRO-2) remission rates of first-line biological classes [anti-tumor necrosis factor (TNF) agents vs anti-integrin vedolizumab vs IL-12/23 inhibitor ustekinumab] in real life cohort.

Methods
Individual level data of 946 adults (588 Crohn’s disease and 358 ulcerative colitis) were retrieved from UR-CARE IBD platform. Adjusted drug survival curves using a pooled logistic model and PRO-2 remission rates for each class of biologicals were calculated and compared.

Results
In Crohn’s disease, no differences in drug survival were observed for anti-TNF agents vs vedolizumab vs ustekinumab as estimated survival with 95% confidence intervals were 0.81 (0.77–0.84) vs 0.89 (0.82–0.96) vs 0.88 (0.79–0.97) at year 1 and 0.52 (0.46–0.58) vs 0.58 (0.37–0.78) vs 0.58 (0.39–0.77) at year 4. In ulcerative colitis, however, anti-TNF agents had shorter drug survival than vedolizumab with estimated drug survival with 95% confidence intervals 0.60 (0.52–0.67) vs 0.76 (0.67–0.84) at year 1 and 0.37 (0.30–0.44) vs 0.50 (0.36–0.64) at year 4. No differences in PRO-2 remission rates were observed between drug classes in Crohn’s disease (P = 0.95), but more patients enjoyed PRO-2 remission in ulcerative colitis treated with anti-TNF agents compared to vedolizumab (94.8 vs 78.9%, P = 0.002).

Conclusion
Our real-world data suggest similar drug persistence and efficacy of first-line treatments with anti-TNF agents, vedolizumab and ustekinumab in Crohn’s disease. In ulcerative colitis, however, drug persistence was higher for vedolizumab compared to anti-TNF agents, but on the cost of lower PRO-2 remission rates.
Prosthetic Rehabilitation for Speech and Swallowing (PReSS): a novel, interdisciplinary approach to head and neck cancer survivorship
Authors: McMillan Holly , Montgomery Pattii , Cardoso Richard 
Published: February 2025

Purpose of review
There are numerous physical, psychosocial, and functional morbidities following glossectomy, particularly impacting speech and swallowing. The lack of systematic rehabilitation programs, including a shortage of clinical rehabilitation and outcomes assessments, limited provider/resource access, and limited collaborative expertise within the interdisciplinary team, may contribute to the perceived hesitation regarding surgical intervention from providers and patients. Prosthetic rehabilitation involving intraoral devices may be beneficial to restore speech and swallowing function after head and neck cancer.

Recent findings
An interdisciplinary approach between speech pathologists and restorative dentists for designing and fabricating intraoral speech prostheses is presented. The Prosthetic Rehabilitation for Speech and Swallowing (PReSS) framework includes three distinct phases:

Summary
This publication outlines the interdisciplinary methodology for designing and fabricating intraoral prosthetics and offers a structured prosthetic program following head and neck cancer treatment. Adopting the PreSS framework may improve speech and swallowing outcomes, improving patients’ quality of life after head and neck cancer treatment.
Integrating Complex Pain Concepts Into Prelicensure Nursing Education
Authors: Firestone Kari A. , Johnston Heidi , Portanova Jaclyn , Jones Kim Dupree 
Published: February 2025

Background:
Unfolding case studies are an active learning strategy that help students integrate knowledge with practical experience, enhancing clinical judgment and easing their transition into professional practice.

Problem:
Chronic pain, a complex health issue, is often inadequately addressed in nursing curricula, leaving prelicensure nursing students unprepared to manage pain effectively in clinical practice, contributing to the academic-practice gap.

Approach:
Using an evidence matrix, faculty interviews, and syllabi analysis across 4 programs, gaps in chronic pain concepts were identified. A 4-term unfolding case study was developed to address these gaps, aligned with the American Association of College of Nursing Essentials and following a patient from acute to chronic pain transition.

Conclusions:
By incorporating evidence-based, active learning strategies like an unfolding case study for a complex concept such as chronic pain management scaffolded across a curriculum, nurse educators can better prepare future nurses for practice.
Reimbursement for Neuroma Surgery Over the Past Decade
Authors: Stearns Stephen A. , Raizman Noah M. , Raasveld Floris V. , Tereshenko Vlad , Gfrerer Lisa , Valerio Ian L. , Winograd Jonathan M. , Eberlin Kyle R. 
Published: February 2025

Purpose
This study aimed to determine how Medicare physician reimbursements for operations related to symptomatic neuromas have changed over the past decade.

Methods
This retrospective review uses the Medicare Physician Fee Schedule Look-up Tool to access reimbursement rates for common peripheral nerve surgeries. Six CPT codes frequently used to bill for neuroma excision, burying in muscle, targeted muscle reinnervation (TMR), and regenerative peripheral nerve interface (RPNI) procedures were identified as representative of the peripheral nerve operations to treat symptomatic neuromas. Physician reimbursement rates were gathered from 2014 to 2024, with gross and inflation-adjusted changes in reimbursement calculated.

Results
For each included peripheral nerve procedure, there was a significant decrease in Medicare physician reimbursement both with and without inflation adjustments. CPT 64905 (for TMR) decreased 30%; CPT 64787 and 15769 (for intramuscular burying and RPNI) decreased 31% and 21%; and CPT 64784, 64782, and 64774 (for neuroma excision) decreased 28%, 26%, and 24%, respectively (all inflation-adjusted), with an average compound annual growth rate of −3.6%. For every 100 neuroma operations in 2014, surgeons in 2018 needed to perform an additional 5.6 to be reimbursed at equal levels. In 2024, surgeons need to perform an additional 27 operations for every 100 to be reimbursed equivalently as 5 years prior.

Conclusions
There has been a consistent decrease in physician reimbursement for procedures related to symptomatic neuromas, highlighting a larger trend in Medicare payments. Continued decline in reimbursement poses risk to these important treatment modalities, which could limit surgeons' ability to provide care to patients.
Seasonal differences in burn injuries and outcomes among adults and older adults at a Canadian provincial burn center
Authors: Hutter Maria Fernanda , Tedesco Diana Julia , Khalaf Fadi , Jeschke Marc G. 
Published: February 2025

Abstract

Background
The literature provides hints of seasonal influences on burn injury occurrence and outcomes in temperate climates. Still, data for geographic regions experiencing significant changes in climate throughout the year is scarce. Especially the influence of seasonal differences in burn incidence and outcomes for older adults (≥60 years old), a particularly vulnerable patient cohort with increased mortality and morbidity compared to adults (18-59 years old), has not been investigated so far. Since burns pose a significant public health concern, we aimed to understand seasonal burn injury admission patterns and outcomes to utilize them for targetable prevention measures and effective resource allocation.

Methods
This retrospective single-center cohort study examined data from adult burn patients (≥18 years) with reported %TBSA (Total Body Surface Area) treated between 2006 and 2020 at a provincial burn center in Ontario, Canada. Patients were stratified based on age group: adults (18-59 years) and older adults (≥60 years) Demographic data, comorbidities, and clinical outcomes were compared.

Results
A total of 2445 eligible patients were enrolled in this study. Most burn injuries occurred in Summer, in which the burn patient population was also significantly younger compared to Winter. Summer admissions showed a greater median %TBSA. In contrast, length of stay per %TBSA (LOS:TBSA) revealed a shorter hospitalization in Summer compared to Winter. However, mortality did not show differences across seasons.

Conclusion
Seasonal variations in the incidence and severity of burn injuries, along with associated fluctuations in LOS:TBSA, exist between age groups. This understanding can assist in tailoring burn prevention programs and aid in anticipating the types of burn injuries that may occur during specific times of the year to enhance patient care strategies.
Adjunctive Vasopressors and Short-Term Mortality in Adults with Septic Shock: A Systematic Review and Meta-Analysis
Authors: Bauer Seth R. , Wieruszewski Patrick M. , Bissell Turpin Brittany D. , Dugar Siddharth , Sacha Gretchen L. , Sato Ryota , Siuba Matthew T. , Schleicher Mary , Vachharajani Vidula , Falck-Ytter Yngve , Morgan Rebecca L. 
Published: February 2025

Abstract

Background
Adjunctive vasopressors are added to norepinephrine in one-third of adults with septic shock in the United States. However, effectiveness of this approach is unclear, and treatment recommendations are based on indirect evidence. We sought to synthesize the direct evidence for adjunctive vasopressor administration in adults with septic shock.

Methods
We searched MEDLINE, Embase, and Cochrane Central Register of Controlled Trials from inception to June 7, 2023. We included randomized clinical trials of adults with septic shock comparing adjunctive treatment with a vasopressin analogue, angiotensin II, methylene blue, hydroxocobalamin, or catecholamine analogue to standard care vasopressors. The primary outcome was short-term mortality (at or before 28-30 days or intensive care discharge). Secondary outcomes included kidney replacement therapy, digital/peripheral ischemia, and venous thromboembolism. Random-effects meta-analyses were conducted to derive risk ratios (RRs) and 95% CIs. The certainty of the evidence was assessed using Grading of Recommendations Assessment, Development, and Evaluation.

Results
Of 6763 records, 17 trials (3813 participants) were included. Compared with standard care, adjunctive vasopressor administration may reduce short-term mortality risk (RR, 0.92 [95% CI, 0.85 to 1.00], low certainty, 17 trials [18 participants]) and likely reduces kidney replacement therapy receipt (RR, 0.92 [95% CI, 0.84 to 1.01], moderate certainty, 8 trials [2408 participants]). Adjunctive vasopressor treatment may increase risk of digital/peripheral ischemia (RR, 2.44 [95% CI, 1.17 to 5.10], low certainty, 9 trials [2981 participants]) and venous thromboembolism (RR, 16.48 [95% CI, 0.96 to 283.17], low certainty, 1 trial [321 participants]). There was some evidence that the pooled estimate for short-term mortality was different (interaction P = 0.13) for trials adjudicated as low risk of bias (RR, 0.95 [95% CI, 0.87 to 1.05]) compared with trials adjudicated as some concerns or high risk of bias (RR, 0.82 [95% CI, 0.69 to 0.97]). The findings were robust to multiple sensitivity and subgroup analyses.

Conclusions
In adults with septic shock, adjunctive vasopressors may lower short-term death risk and likely lower kidney replacement therapy risk, but may increase risk of adverse effects. In the United States, adjunctive vasopressor use prevalence in septic shock is disconnected from the low evidence certainty for a favorable mortality-to-risk profile.

Registration
PROSPERO CRD42023427984
PTP1B and zonulin failed to predict the modification of muscle mass in critically ill patients with septic shock
Authors: Caroline Lemaitre , Zoé Demailly , Thomas Clavier , Christophe Girault , Gaëtan Béduneau , Dorothée Carpentier , Marchalot Antoine , Christine Bôle-Feysot , Steven Grange , Vincent Richard , Moïse Coëffier , Fabienne Tamion 
Published: February 2025

Abstract

Background
Proteolyse is one of the causes of loss of lean body mass, and depend of insulin. Proteintyrosine phosphatase 1B (PTP1B) and intestinal permeability (evaluated by zonulin) contribute of insulin metabolism. The objectives were to explore the relationship between PTP1B, Zonulin level and body composition during septic shock in humans.

Material and Methods
Prospective study including patients admitted to intensive care unit (ICU) for septic shock. Blood samples were collected on days 1 (D1) and 4 (D4) for study expression of PTPT1b (PCR) and zonulin. Muscle mass was evaluated by Fat-Free Mass (FFM) (by Bioelectrical impedance analysis) and rectum femoris cross-sectional area by ultrasound.

Results
We included 52 patients with a mean IGSII 53 [39-65], and a mortality in ICU of 32%. Between D1 and D4, aera of right quadriceps muscle (ARQ) and average of quadriceps muscles (AAQ) decreased (p = 0.002 and 0.009 respectively). We observed no modification in FFM. Median of PTP1b at D1 was 5.03 [2.36-10.96]. Median of plasmatic zonulin at D1 was 156.6 ng/ml [56.3-277.9]. We did not find any correlation between PTP1b, zonulin expression and muscle composition. The mortality rate was more important in patients with a low average quadriceps thickness (QT) or quadriceps area (QA) (p < 0.01), and tendency for patients who had an elevated zonulin in admission. By contrast, we did not observe significant associations between fat-free mass and PTP1B and mortality at D28.

Conclusion
We observed a trend of correlation between the whole blood PTPN1 gene expression at D1 and D4/D1 TLQ, because this is the only data which has a potential to address the relationship body mass change and proteolysis.

Keys words: Body composition, malnutrition, PTB1B, septic shock, Zonulin
Machine Learning and Shock Indices-Derived Score for Predicting Contrast-Induced Nephropathy in ACS Patients
Authors: Yavuz Yunus Emre , Tatar Sefa , Akıllı Hakan , Aslan Muzaffer , İçli Abdullah 
Published: February 2025

Abstract

Background
Contrast-induced nephropathy (CIN) is a serious complication following acute coronary syndrome (ACS), leading to increased morbidity and mortality. Machine learning (ML), combined with parameters such as shock indices, can potentially improve CIN risk prediction by analyzing complex variable interactions and creating accessible, clinically applicable models.

Methods
This retrospective case-control study included 719 ACS patients who underwent percutaneous coronary intervention (PCI). Patients were divided into two groups (CIN and non-CIN), and clinical, procedural, and hemodynamic parameters, including shock indices, were analyzed using machine learning algorithms. A new predictive model, CIN-Predict 5, was developed using the Gradient Boosting Machine (GBM) algorithm, incorporating clinically relevant and statistically significant variables. Correlations between model predictions and secondary outcomes, including in-hospital mortality and hospitalization duration, were evaluated.

Results
Among the variables used in the GBM algorithm, the Modified Shock Index emerged as the most significant predictor, with an importance score of 0.25. The CIN-Predict 5 model achieved an AUC of 0.87, outperforming the Mehran Risk Score (AUC = 0.75) for predicting CIN. The secondary outcomes showed that CIN-Predict 5 correlated significantly with in hospital mortality (r = 0.16, p < 0.001) and hospitalization duration (r = 0.20, p < 0.001).

Conclusions
The GBM-based model we developed, utilizing shock indices and derived through ML, provides a practical tool for early identification of high-risk CIN patients post-ACS, enabling timely preventive strategies and improving clinical decision-making.
Resuscitative Endovascular Balloon Occlusion of the Aorta: What You Need to Know
Authors: Shaw Joanna , Brenner Megan 
Published: February 2025

ABSTRACT
Hemorrhage remains one of the leading causes of death from traumatic injury in both the civilian and military populations. Resuscitative endovascular balloon occlusion of the aorta (REBOA) is a minimally invasive technique that can be used to treat hemorrhage in the critically ill. An alternative to maximally invasive methods such as resuscitative thoracotomy, REBOA is a temporizing measure to prevent exsanguination and allow for transition to definitive hemorrhage control. It is easily deployed by trained users and does not require surgical expertise to place. Its use has increased over the past decade with a growing body of literature that suggests it improves outcomes in select hemorrhagic trauma patients compared with patients who do not receive REBOA. REBOA has also been used for select nontraumatic cases. Judicious patient selection, knowing the technical aspects of placing REBOA, and clarity regarding its indications are key to maximize its efficacy as a mitigatory tool in hemorrhagic shock. This “What You Need To Know” review presents current evidence regarding use of REBOA for the acute care surgeon.

LEVEL OF EVIDENCE
Level V.
Rapid and wash-free anti-drug antibody assay enabled by the complementary nanoluciferase biosensor
Authors: Sun Ruoxuan , Qian Mark G. , Zhang Xiaobin 
Published: February 2025

AbstractBiotherapeutics have demonstrated remarkable therapeutic efficacy across a wide range of diseases; however, their clinical application is often hindered by the development of anti-drug antibodies (ADAs). Traditionally, ADA monitoring has relied on ligand-binding assays (LBAs) such as enzyme-linked immunosorbent assays (ELISA) or electrochemiluminescence assays (ECLIA). Although effective, these methods require multiple washing and incubation steps, extending data generation time to several hours or even days. In contrast, homogeneous immunoassays offer a promising alternative due to their “mix-and-read” feature, which significantly reduces operational complexity, time, and cost compared to conventional LBAs. In this study, we explored the feasibility of rapid ADA detection using a wash-free homogeneous assay based on the split nanoluciferase (SplitNluc) biosensor system. Through case studies involving diverse therapeutic modalities including antibody-drug conjugates (ADC), Fc-fusion protein, Fc-less multidomain biotherapeutics (MDB), and single-domain antibody (SdAb), we demonstrated that the SplitNluc platform is a versatile and efficient tool for robust and rapid ADA monitoring. This approach not only streamlines the detection process but also holds potential for broader applications in biotherapeutic development and clinical monitoring.
Ultradeep N-glycoproteome Atlas of Mouse Reveals Spatiotemporal Signatures of Brain Aging and Neurodegenerative Diseases
Authors: Fang Pan , Yu Xiangming , Ding MengYang , Cong Qifei , Jiang Hongyu , Shi Qi , Zhao Weiwei , Zheng Weimin , Li Yingning , Ling Zixiang , Kong WeiJun , Yang Pengyuan , Shen Huali 
Published: February 2025

AbstractThe current depth of site-specific N-glycoproteomics is insufficient to fully characterize glycosylation events in biological samples. Herein, we achieved an ultradeep and precision analysis of the N-glycoproteome of mouse tissues by integrating multiple workflows. The largest N-glycoproteomic dataset to date was established on mice, which contained 91,972 precursor glycopeptides, 62,216 glycoforms, 8,939 glycosites and 4,563 glycoproteins. The database consisted of 6.8 million glyco-spectra (containing oxonium ions), among which 160,928 were high-quality spectra with confident N-glycopeptide identifications. The large-scale and high-quality dataset enhanced the performance of current artificial intelligence models for glycopeptide tandem spectrum prediction. Using this ultradeep dataset, we observed tissue specific microheterogeneity and functional implications of protein glycosylation in mice. Furthermore, the region-resolved brain N-glycoproteomes for Alzheimer’s Diseases, Parkinson Disease and aging mice revealed the spatiotemporal signatures and distinct pathological functions of the N-glycoproteins. A comprehensive database resource of experimental N-glycoproteomic data from this study and previous literatures were further established. This N-glycoproteome atlas serves as a promising tool for revealing the role of protein glycosylation in biological systems.
Highly accurate prediction of broad-spectrum antiviral compounds with DeepAVC
Authors: Kang Boming , Zhao Yang , Chen Xingyu , Fan Rui , You Fuping , Cui Qinghua 
Published: February 2025

AbstractLethal viruses, such as HIV, pose a significant threat to human life, with each pandemic causing millions of fatalities globally. Small-molecule antiviral drugs provide an efficient and convenient approach to antiviral therapy by either inhibiting viral activity or activating the host immune system. However, conventional antiviral drug discovery is often labor-intensive and time-consuming due to the vast chemical space. Although some existing computational models mitigate this problem, there remains a lack of rapid and accurate method specifically designed for antiviral drug discovery. Here, we propose DeepAVC, a universal framework based on pre-trained large language models, for highly accurate broad-spectrum antiviral compounds discovery, including two models, DeepPAVC for phenotype-based prediction and DeepTAVC for target-based prediction. As a result, DeepAVC greatly outperforms otherin silicomethods. More importantly, in the top predictions, MNS and NVP-BVU972 were identified as novel compounds with promising broad-spectrum antiviral activities byin vitroexperiments. Finally, DeepAVC demonstrates high interpretability, one of the bottlenecks of current AI methods, due to its ability of analyzing key functional groups of antiviral compounds and important binding sites on targets.
Pamrevlumab did not meet its primary endpoint for non-ambulatory patients with Duchenne Muscular Dystrophy: the LELANTOS-1 trial
Authors: Connolly Anne M. , Wong Brenda L. , Phan Han C. , Mercuri Eugenio , Cai Xiaotang , Tian Cuixia , Lucia Silvana De , Nelson Stanley F. , Péréon Yann , Previtali Stefano C. , Wang Steven , Gambetti Olga V. , Brandsema John F. , Carrier Ewa 
Published: February 2025

ABSTRACTBackgroundIn Duchenne muscular dystrophy (DMD), fibrosis is linked to connective tissue growth factor (CTGF) overexpression. Pamrevlumab, a fully human monoclonal antibody, inhibits CTGF activity and showed promise as a DMD treatment in a phase 2 trial.ObjectiveLELANTOS-1 (NCT04371666) was a global phase 3 study of the safety and efficacy of pamrevlumab for non-ambulatory males ≥12 years old with DMD.MethodsPatients were randomized 1:1 to pamrevlumab 35 mg/kg every 2 weeks for 52 weeks or placebo. All received a stable corticosteroid regimen (deflazacort or prednisone/prednisolone). Primary endpoint was total Performance of Upper Limb (PUL) v2.0 score change from baseline to Week 52 in the modified intent-to-treat (mITT) set (baseline PUL score ≥2). Treatment-emergent adverse events (TEAEs) were noted. Patients who completed the main study period were eligible to enroll in the open-label extension (OLE).ResultsNinety-eight patients (mean [SD] age, 15.5 [2.57] years) enrolled; 48 received pamrevlumab and 49 received placebo. Between-group baseline characteristics were similar. In the mITT set (mean [SD] age, 15.5 [2.64] years; pamrevlumab, n=41; placebo, n=42), the total PUL v2.0 score change was not significantly different (p=0.8802). The pamrevlumab group had more grip strength deterioration than placebo in dominant (p=0.0161) and nondominant hands (p=0.0052). Most patients (pamrevlumab, n=45/48 [93.8%]; placebo, n=48/49 [98.0%]) experienced TEAEs (most mild/moderate). One death occurred in the pamrevlumab group (unrelated to study drug). The OLE mITT set included 72 patients. OLE efficacy and safety were consistent with the main study period. No deaths occurred during the OLE.ConclusionsPamrevlumab failed to meet the primary endpoint. Its future as a DMD treatment is uncertain.Trial RegistrationClinicalTrials.gov Identifier:NCT04371666